Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
JPRN-jRCT2071260068 SFG-02 Urinary Incontinence Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
JPRN-jRCT2071260068 clinical trial report covering SFG-02, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734012 Mycophenolate Mofetil Scleroderma, Systemic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734012 clinical trial report covering Mycophenolate Mofetil, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07732491 Culmerciclib Advanced HER2-Positive Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07732491 clinical trial report covering Culmerciclib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733466 Cetuximab Squamous cell carcinoma of the oral cavity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733466 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734870 Tirzepatide Pseudopelade Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734870 clinical trial report covering Tirzepatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733934 Teverelix Trifluoroacetate Prostatic Hyperplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733934 clinical trial report covering Teverelix Trifluoroacetate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733180 Tislelizumab Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733180 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734038 Venetoclax Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734038 clinical trial report covering Venetoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07737925 Xaluritamig Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07737925 clinical trial report covering Xaluritamig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262884 HX9428 Wet age-related macular degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
CTR20262884 clinical trial report covering HX9428, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262897 Albipagrastim alfa Bone marrow depression Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
CTR20262897 clinical trial report covering Albipagrastim alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262849 XH-S003 Glomerulonephritis, IGA Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
CTR20262849 clinical trial report covering XH-S003, Phase 2, endpoints, sponsor, geography, readout timing and development white space.